Hui JYC. Epidemiology and etiology of sarcomas. Surg Clin N Am. 2016;96(5):901–14.

PubMed  Article  Google Scholar 

Stiller CA, Trama A, Serraino D, Rossi S, Navarro C, Chirlaque MD, Casali PG, RARECARE Working Group. Descriptive epidemiology of sarcomas in Europe: Report from the RARECARE project. Eur J Cancer. 2013;49(3):684–95.

CAS  PubMed  Article  Google Scholar 

Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):83–103.

PubMed  Article  Google Scholar 

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.

PubMed  Article  Google Scholar 

Kaatsch P. Epidemiology of childhood cancer. Cancer Treat Rev. 2010;36(4):277–85.

PubMed  Article  Google Scholar 

WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours. WHO classification of tumours, 5th edition, volume 3, vol. 3. 5th ed. Lyon: IARC; 2020.

Google Scholar 

Grünewald TG, Alonso M, Avnet S, Banito A, Burdach S, Cidre-Aranaz F, di Pompo G, Distel M, Dorado-Garcia H, Garcia-Castro J, González-González L, Grigoriadis AE, Kasan M, Koelsche C, Krumbholz M, Lecanda F, Lemma S, Longo DL, Madrigal-Esquivel C, et al. Sarcoma treatment in the era of molecular medicine. EMBO Mol Med. 2020;12(11):e11131.

PubMed  PubMed Central  Article  Google Scholar 

de Pinieux G, Karanian M, le Loarer F, le Guellec S, Chabaud S, Terrier P, Bouvier C, Batistella M, Neuville A, Robin YM, Emile JF, Moreau A, Larousserie F, Leroux A, Stock N, Lae M, Collin F, Weinbreck N, Aubert S, et al. Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network. PLoS One. 2021;16(2):e0246958.

PubMed  PubMed Central  Article  Google Scholar 

Burns J, Wilding CP, L Jones R, H Huang P. Proteomic research in sarcomas - current status and future opportunities. Semin Cancer Biol. 2020;61:56–70.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Roberts RD, Lizardo MM, Reed DR, Hingorani P, Glover J, Allen-Rhoades W, Fan T, Khanna C, Sweet-Cordero EA, Cash T, Bishop MW, Hegde M, Sertil AR, Koelsche C, Mirabello L, Malkin D, Sorensen PH, Meltzer PS, Janeway KA, et al. Provocative questions in osteosarcoma basic and translational biology: a report from the Children's Oncology Group. Cancer. 2019;125(20):3514–25.

PubMed  Article  Google Scholar 

Nakano K, Takahashi S. Precision medicine in soft tissue sarcoma treatment. Cancers. 2020;12(1):221.

CAS  PubMed Central  Article  Google Scholar 

Judson I, Verweij J, Gelderblom H, Hartmann JT, Schöffski P, Blay JY, Kerst JM, Sufliarsky J, Whelan J, Hohenberger P, Krarup-Hansen A, Alcindor T, Marreaud S, Litière S, Hermans C, Fisher C, Hogendoorn PC, dei Tos A, van der Graaf W, European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15(4):415–23.

CAS  PubMed  Article  Google Scholar 

Blay J-Y, Leahy MG, Nguyen BB, Patel SR, Hohenberger P, Santoro A, Staddon AP, Penel N, Piperno-Neumann S, Hendifar A, Lardelli P, Nieto A, Alfaro V, Chawla SP. Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas. Eur J Cancer. 2014;50(6):1137–47.

CAS  PubMed  Article  Google Scholar 

Gennatas S, Chamberlain F, Carter T, Slater S, Cojocaru E, Lambourn B, Stansfeld A, Todd R, Verrill M, Ali N, Jones RL, Simmonds P, Keay N, McCarty H, Strauss S, Karavasilis V, Dileo P, Benson C. Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland. Clin Sarcoma Res. 2020;10:9.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Chawla SP, Papai Z, Mukhametshina G, Sankhala K, Vasylyev L, Fedenko A, Khamly K, Ganjoo K, Nagarkar R, Wieland S, Levitt DJ. First-line aldoxorubicin vs doxorubicin in metastatic or locally advanced unresectable soft-tissue sarcoma: a phase 2b randomized clinical trial. JAMA Oncol. 2015;1(9):1272–80.

PubMed  Article  Google Scholar 

Tap WD, Papai Z, van Tine BA, Attia S, Ganjoo KN, Jones RL, Schuetze S, Reed D, Chawla SP, Riedel RF, Krarup-Hansen A, Toulmonde M, Ray-Coquard I, Hohenberger P, Grignani G, Cranmer LD, Okuno S, Agulnik M, Read W, et al. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2017;18(8):1089–103.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Ryan CW, Merimsky O, Agulnik M, Blay JY, Schuetze SM, van Tine BA, Jones RL, Elias AD, Choy E, Alcindor T, Keedy VL, Reed DR, Taub RN, Italiano A, Garcia del Muro X, Judson IR, Buck JY, Lebel F, Lewis JJ, et al. PICASSO III: a phase III, placebo-controlled study of doxorubicin with or without palifosfamide in patients with metastatic soft tissue sarcoma. J Clin Oncol. 2016;34(32):3898–905.

CAS  PubMed  Article  Google Scholar 

Vlenterie M, Litière S, Rizzo E, Marréaud S, Judson I, Gelderblom H, le Cesne A, Wardelmann E, Messiou C, Gronchi A, van der Graaf WTA. Outcome of chemotherapy in advanced synovial sarcoma patients: review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entity. Eur J Cancer. 2016;58:62–72.

PubMed  Article  Google Scholar 

Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, Rothermundt C, Wood Z, Benson C, Ali N, Marples M, Veal GJ, Jamieson D, Küver K, Tirabosco R, Forsyth S, Nash S, Dehbi HM, Beare S. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol. 2017;18(10):1397–410.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Tap WD, Wagner AJ, Schöffski P, Martin-Broto J, Krarup-Hansen A, Ganjoo KN, Yen CC, Abdul Razak AR, Spira A, Kawai A, le Cesne A, van Tine BA, Naito Y, Park SH, Fedenko A, Pápai Z, Soldatenkova V, Shahir A, Mo G, et al. effect of doxorubicin plus olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas: the ANNOUNCE randomized clinical trial. JAMA. 2020;323(13):1266–76.

CAS  PubMed  PubMed Central  Article  Google Scholar 

National Comprehensive Cancer Network, Clinical Practice Guidelines in Oncology (NCCN Guidelines): Bone cancer, version 2.2019.

Casali PG, et al. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv79–95.

CAS  PubMed  Article  Google Scholar 

Horbach L, Sinigaglia M, da Silva CA, Olguins DB, Gregianin LJ, Brunetto AL, Brunetto AT, Roesler R, de Farias CB. Gene expression changes associated with chemotherapy resistance in Ewing sarcoma cells. Mol Clin Oncol. 2018;8(6):719–24.

CAS  PubMed  PubMed Central  Google Scholar 

van Oosterwijk JG, Herpers B, Meijer D, Briaire-de Bruijn IH, Cleton-Jansen AM, Gelderblom H, van de Water B, Bovée JVMG. Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma <em>in vitro</em>: BCL-2 family members cause chemoresistance. Ann Oncol. 2012;23(6):1617–26.

PubMed  Article  Google Scholar 

Jimenez RE, Zalupski MM, Frank JJ, du W, Ryan JR, Lucas DR. Multidrug resistance phenotype in high grade soft tissue sarcoma. Cancer. 1999;86(6):976–81.

CAS  PubMed  Article  Google Scholar 

Li X, Shen JK, Hornicek FJ, Xiao T, Duan Z. Noncoding RNA in drug resistant sarcoma. Oncotarget. 2017;8(40):69086–104.

PubMed  PubMed Central  Article  Google Scholar 

Casali PG, et al. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv68–78.

CAS  PubMed  Article  Google Scholar 

Judson I, Bulusu R, Seddon B, Dangoor A, Wong N, Mudan S. UK clinical practice guidelines for the management of gastrointestinal stromal tumours (GIST). Clin Sarcoma Res. 2017;7(1):6.

PubMed  PubMed Central  Article  Google Scholar 

Casali PG, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv268–9.

CAS  PubMed  Article  Google Scholar 

van der Graaf WT, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879–86.

PubMed  Article  Google Scholar 

STIVARGA (regorafenib) Prescribing Information. Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA. 2020.

Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279(5350):577–80.

CAS  PubMed  Article  Google Scholar 

Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CDM, Fletcher JA. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299(5607):708–10.

CAS  PubMed  Article  Google Scholar 

Demetri GD, von Mehren M, Blanke CD, van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347(7):472–80.

CAS  PubMed  Article  Google Scholar 

Kelly CM, Gutierrez Sainz L, Chi P. T